teaser
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
The FDA has approved the investigational new drug application (NDA) for Enzon Pharmaceuticals’ HIF-1 alpha antagonist drug.
HIF-1 alpha is a target in many cancer types, including common solid tumours. It is a key regulator of a large number of genes important in cancer biology, such as angiogenesis, cell proliferation, apoptosis and cell invasion. HIF-1 alpha is low in normal cells but high intracellular concentrations have been observed in a variety of cancers. High HIF-1 alpha concentrations are correlated with poor prognosis and resistance to therapy.
